Astellas wins FDA nod for antifungal Cresemba
This article was originally published in Scrip
Astellas won the FDA’s approval to market Cresemba (isavuconazonium sulfate) in the US as a treatment for two rare but serious infections, invasive aspergillosis and invasive mucormycosis.
You may also be interested in...
Pfizer will develop the novel antifungal fosmanogepix. The big pharma has made several other recent anti-infective deals, including when it expanded its BioNTech vaccine alliance to include COVID-19.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.